Windtree Therapeutics is a biotechnology business based in the US. Windtree Therapeutics shares (WINT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.51 – an increase of 6.1% over the previous week.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.51 |
|---|---|
| 52-week range | $0.45 - $22.36 |
| 50-day moving average | $1.70 |
| 200-day moving average | $4.93 |
| Wall St. target price | $7.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-19.03 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.47 from 2024-11-19
| 1 week (2024-11-14) | -4.08% |
|---|---|
| 1 month (2024-10-21) | -56.07% |
| 3 months (2024-08-21) | -95.54% |
| 6 months (2024-05-21) | -88.94% |
| 1 year (2023-11-21) | -49.02% |
|---|---|
| 2 years (2022-11-21) | -99.70% |
| 3 years (2021-11-19) | 1403.9988 |
| 5 years (2019-11-21) | 9125.9814 |
| Gross profit TTM | $-17,787,000 |
|---|---|
| Return on assets TTM | -44.76% |
| Return on equity TTM | -150.8% |
| Profit margin | 0% |
| Book value | $5.90 |
| Market Capitalization | $4.9 million |
TTM: trailing 12 months
We're not expecting Windtree Therapeutics to pay a dividend over the next 12 months.
Windtree Therapeutics's shares were split on a 1:18 basis on 21 April 2024 . So if you had owned 18 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Windtree Therapeutics shares – just the quantity. However, indirectly, the new 1700% higher share price could have impacted the market appetite for Windtree Therapeutics shares which in turn could have impacted Windtree Therapeutics's share price.
Over the last 12 months, Windtree Therapeutics's shares have ranged in value from as little as $0.4515 up to $22.3614. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Windtree Therapeutics's is 0.643. This would suggest that Windtree Therapeutics's shares are less volatile than average (for this exchange).
Windtree Therapeutics, Inc. , a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.